PMID: 108938Sep 1, 1978

Daily short course (6 months) chemotherapy for treatment of pulmonary tuberculosis in Nigerians: a preliminary report

African Journal of Medicine and Medical Sciences
B O Onadeko, E O Sofowora


A trial of daily short courses (6 months) chemotherapy of previously untreated cases of pulmonary tuberculosis in Nigerians was carried out, using two regimens containing rifampicin. All patients had sputum conversion at 3 months, with over 90% of them being sputum-negative at 2 months. There was evidence of radiographic clearance in all the patients at 6 months. It is suggested that patients who still had extensive radiographic lesions at 6 months, though bacteriologically sterile, should have their chemotherapy extended to 9 months to reduce the chance of developing a bacteriological relapse. It was observed that the addition of streptomycin did not make any important contribution to the therapeutic success of rifampicin-isoniazid regimen. No bacteriological relapse was encountered 3 months after the cessation of chemotherapy. Rifampicin was well tolerated and toxic reactions were virtually non-existent. This study confirms the efficacy of short course regimens containing rifampicin. The regimen is advocated, especially in areas where patients' co-operation at taking the 18 month standard treatment cannot be guaranteed.

Related Concepts

Drug Combinations
Tuberculosis, Pulmonary

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Systemic Juvenile Idiopathic Arthritis

Systemic juvenile idiopathic arthritis is a rare rheumatic disease that affects children. Symptoms include joint pain, but also fevers and skin rashes. Here is the latest on this disease.

Chromatin Regulation and Circadian Clocks

The circadian clock plays an important role in regulating transcriptional dynamics through changes in chromatin folding and remodelling. Discover the latest research on Chromatin Regulation and Circadian Clocks here.

Central Pontine Myelinolysis

Central Pontine Myelinolysis is a neurologic disorder caused most frequently by rapid correction of hyponatremia and is characterized by demyelination that affects the central portion of the base of the pons. Here is the latest research on this disease.

Myocardial Stunning

Myocardial stunning is a mechanical dysfunction that persists after reperfusion of previously ischemic tissue in the absence of irreversible damage including myocardial necrosis. Here is the latest research.

Pontocerebellar Hypoplasia

Pontocerebellar hypoplasias are a group of neurodegenerative autosomal recessive disorders with prenatal onset, atrophy or hypoplasia of the cerebellum, hypoplasia of the ventral pons, microcephaly, variable neocortical atrophy and severe mental and motor impairments. Here is the latest research on pontocerebellar hypoplasia.

Cell Atlas Along the Gut-Brain Axis

Profiling cells along the gut-brain axis at the single cell level will provide unique information for each cell type, a three-dimensional map of how cell types work together to form tissues, and insights into how changes in the map underlie health and disease of the GI system and its crosstalk with the brain. Disocver the latest research on single cell analysis of the gut-brain axis here.

Chronic Traumatic Encephalopathy

Chronic Traumatic Encephalopathy (CTE) is a progressive degenerative disease that occurs in individuals that suffer repetitive brain trauma. Discover the latest research on traumatic encephalopathy here.